Prima BioMed Receives Positive Scientific Advice From the European Medicines Agency for Its Lead Product, IMP321 - Seite 3

About Prima BioMed

Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Prima's original product, called CVac, is an ex vivo dendritic cell priming therapy that in May 2015 yielded favourable Phase II data in second remission ovarian cancer patients. Prima is currently seeking partners for further development of this therapy. Prima's current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is soluble LAG-3, is a T cell immunostimulatory factor for cancer chemoimmunotherapy which has completed early Phase II trials. A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.

Prima BioMed is listed on the Australian Stock Exchange, on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.

For further information please contact:

¹ In HER2-negative metastatic breast cancer PFS can be as low as 6 months - see Miller et. al., N Engl J Med. 2007 Dec 27; 357(26):2666-76.

² See Gray et. al., J Clin Oncol. 2009 Oct 20; 27(30): 4966-4972.

³ See Brignone et.al., J Transl Med. 2010 Jul 23;8:71.

Prima BioMed Ltd:
Stuart Roberts
Global Head of Investor Relations
[phone]
[e-mail]

Australia Investor/Media:
Mr Matthew Gregorowski
Citadel-MAGNUS
[phone]
[e-mail]

Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
[phone]
[e-mail]